We received the Marketing Authorization for BoxGripal® medicine8 December
Hereby, VIVA Pharm reports that it received Marketing Authorization (РК-ЛС-5№023417) for BoxGripal® medicine (powder for oral solution) on December 8, 2017.
BoxGrypal® (paracetamol 325 mg, phenyramine maleate 20 mg, phenylephrine hydrochloride 10 mg) is a combination medication that has antipyretic, decongestive, analgesic, and antihistamine action. It’s recommended for short-term symptomatic therapy in acute respiratory viral infections, influenza, accompanied by chills, fever, headache, symptoms of rhinitis, sneezing, and muscle pain. It’s non-prescription medicinal product.